Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback